Shopping Cart 0
Cart Subtotal
USD 0

Spinal Muscular Atrophy (SMA)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Spinal Muscular Atrophy (SMA)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Muscular Atrophy (SMA)-Pipeline Review, H2 2017, provides an overview of the Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline landscape.

Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important cells are responsible for supplying electrical and chemical messages to muscle cells. Without the proper input from the motor neurons, muscle cells cannot function properly. The muscle cells will, therefore, become much smaller (atrophy) and will produce symptoms of muscle weakness. This can affect walking, crawling, breathing, swallowing, and head and neck control.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Muscular Atrophy (SMA)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 1, 13 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively.

Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Muscular Atrophy (SMA) (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Spinal Muscular Atrophy (SMA) (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Spinal Muscular Atrophy (SMA)-Overview 6

Spinal Muscular Atrophy (SMA)-Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Spinal Muscular Atrophy (SMA)-Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Spinal Muscular Atrophy (SMA)-Companies Involved in Therapeutics Development 23

AveXis Inc 23

Biogen Inc 23

Cytokinetics Inc 24

F. Hoffmann-La Roche Ltd 24

Genethon SA 25

Genzyme Corp 25

Kowa Company Ltd 26

Neurotune AG 26

Novartis AG 27

Paratek Pharmaceuticals Inc 27

Recursion Pharmaceuticals Inc 28

Sarepta Therapeutics Inc 28

Scholar Rock Inc 29

Spotlight Innovation Inc 29

Translate Bio Inc 30

WAVE Life Sciences Ltd 30

Spinal Muscular Atrophy (SMA)-Drug Profiles 31

AAD-2004-Drug Profile 31

ALB-111-Drug Profile 32

Antisense Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy-Drug Profile 33

Antisense Oligonucleotides for Spinal Muscular Atrophy-Drug Profile 34

AVXS-101-Drug Profile 35

branaplam-Drug Profile 41

CK-2127107-Drug Profile 42

Gene Therapy to Activate SMN for Spinal Muscular Atrophy-Drug Profile 48

Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy-Drug Profile 49

Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy-Drug Profile 50

K-828SP-Drug Profile 51

NT-1654-Drug Profile 52

nusinersen-Drug Profile 53

olesoxime-Drug Profile 62

Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy-Drug Profile 67

Oligonucleotides to Activate SMN2 for Spinal Muscular Atrophy Type 1-Drug Profile 68

PMO-25-Drug Profile 69

PTKSMA-1-Drug Profile 70

RG-7916-Drug Profile 71

Small Molecules 1 for Spinal Muscular Atrophy-Drug Profile 73

Small Molecules 2 for Spinal Muscular Atrophy-Drug Profile 74

Small Molecules for Central Nervous System Disorders-Drug Profile 75

Small Molecules for Spinal Muscular Atrophy-Drug Profile 76

Small Molecules for Spinal Muscular Atrophy-Drug Profile 77

Small Molecules for Spinal Muscular Atrophy-Drug Profile 78

Small Molecules to Activate SMN2 for Spinal Muscular Atrophy-Drug Profile 79

Small Molecules to Activate SMN2 for Spinal Muscular Atrophy-Drug Profile 80

Small Molecules to Inhibit GSK-3 for Spinal Muscular Atrophy-Drug Profile 81

SRK-015-Drug Profile 82

STL-182-Drug Profile 84

tirasemtiv-Drug Profile 85

Xcel-hNu-Drug Profile 96

Xcel-hNuP-Drug Profile 97

Spinal Muscular Atrophy (SMA)-Dormant Projects 98

Spinal Muscular Atrophy (SMA)-Discontinued Products 100

Spinal Muscular Atrophy (SMA)-Product Development Milestones 101

Featured News & Press Releases 101

Appendix 115

Methodology 115

Coverage 115

Secondary Research 115

Primary Research 115

Expert Panel Validation 115

Contact Us 115

Disclaimer 116


List Of Figure

List of Figures

Number of Products under Development for Spinal Muscular Atrophy (SMA), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Spinal Muscular Atrophy (SMA), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by AveXis Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Biogen Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Cytokinetics Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Genethon SA, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Genzyme Corp, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Kowa Company Ltd, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Neurotune AG, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Novartis AG, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Paratek Pharmaceuticals Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Recursion Pharmaceuticals Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Sarepta Therapeutics Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Scholar Rock Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Spotlight Innovation Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Translate Bio Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by WAVE Life Sciences Ltd, H2 2017

Spinal Muscular Atrophy (SMA)-Dormant Projects, H2 2017

Spinal Muscular Atrophy (SMA)-Dormant Projects, H2 2017 (Contd..1), H2 2017

Spinal Muscular Atrophy (SMA)-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Spinal Muscular Atrophy (SMA) Therapeutic Products under Development, Key Players in Spinal Muscular Atrophy (SMA) Therapeutics, Spinal Muscular Atrophy (SMA) Pipeline Overview, Spinal Muscular Atrophy (SMA) Pipeline, Spinal Muscular Atrophy (SMA) Pipeline Assessment


Companies

Spinal Muscular Atrophy (SMA) Therapeutic Products under Development, Key Players in Spinal Muscular Atrophy (SMA) Therapeutics, Spinal Muscular Atrophy (SMA) Pipeline Overview, Spinal Muscular Atrophy (SMA) Pipeline, Spinal Muscular Atrophy (SMA) Pipeline Assessment

Spinal Muscular Atrophy (SMA)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Muscular Atrophy (SMA)-Pipeline Review, H2 2017, provides an overview of the Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline landscape.

Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important cells are responsible for supplying electrical and chemical messages to muscle cells. Without the proper input from the motor neurons, muscle cells cannot function properly. The muscle cells will, therefore, become much smaller (atrophy) and will produce symptoms of muscle weakness. This can affect walking, crawling, breathing, swallowing, and head and neck control.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Muscular Atrophy (SMA)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 1, 13 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively.

Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Muscular Atrophy (SMA) (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Spinal Muscular Atrophy (SMA) (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Spinal Muscular Atrophy (SMA)-Overview 6

Spinal Muscular Atrophy (SMA)-Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Spinal Muscular Atrophy (SMA)-Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Spinal Muscular Atrophy (SMA)-Companies Involved in Therapeutics Development 23

AveXis Inc 23

Biogen Inc 23

Cytokinetics Inc 24

F. Hoffmann-La Roche Ltd 24

Genethon SA 25

Genzyme Corp 25

Kowa Company Ltd 26

Neurotune AG 26

Novartis AG 27

Paratek Pharmaceuticals Inc 27

Recursion Pharmaceuticals Inc 28

Sarepta Therapeutics Inc 28

Scholar Rock Inc 29

Spotlight Innovation Inc 29

Translate Bio Inc 30

WAVE Life Sciences Ltd 30

Spinal Muscular Atrophy (SMA)-Drug Profiles 31

AAD-2004-Drug Profile 31

ALB-111-Drug Profile 32

Antisense Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy-Drug Profile 33

Antisense Oligonucleotides for Spinal Muscular Atrophy-Drug Profile 34

AVXS-101-Drug Profile 35

branaplam-Drug Profile 41

CK-2127107-Drug Profile 42

Gene Therapy to Activate SMN for Spinal Muscular Atrophy-Drug Profile 48

Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy-Drug Profile 49

Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy-Drug Profile 50

K-828SP-Drug Profile 51

NT-1654-Drug Profile 52

nusinersen-Drug Profile 53

olesoxime-Drug Profile 62

Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy-Drug Profile 67

Oligonucleotides to Activate SMN2 for Spinal Muscular Atrophy Type 1-Drug Profile 68

PMO-25-Drug Profile 69

PTKSMA-1-Drug Profile 70

RG-7916-Drug Profile 71

Small Molecules 1 for Spinal Muscular Atrophy-Drug Profile 73

Small Molecules 2 for Spinal Muscular Atrophy-Drug Profile 74

Small Molecules for Central Nervous System Disorders-Drug Profile 75

Small Molecules for Spinal Muscular Atrophy-Drug Profile 76

Small Molecules for Spinal Muscular Atrophy-Drug Profile 77

Small Molecules for Spinal Muscular Atrophy-Drug Profile 78

Small Molecules to Activate SMN2 for Spinal Muscular Atrophy-Drug Profile 79

Small Molecules to Activate SMN2 for Spinal Muscular Atrophy-Drug Profile 80

Small Molecules to Inhibit GSK-3 for Spinal Muscular Atrophy-Drug Profile 81

SRK-015-Drug Profile 82

STL-182-Drug Profile 84

tirasemtiv-Drug Profile 85

Xcel-hNu-Drug Profile 96

Xcel-hNuP-Drug Profile 97

Spinal Muscular Atrophy (SMA)-Dormant Projects 98

Spinal Muscular Atrophy (SMA)-Discontinued Products 100

Spinal Muscular Atrophy (SMA)-Product Development Milestones 101

Featured News & Press Releases 101

Appendix 115

Methodology 115

Coverage 115

Secondary Research 115

Primary Research 115

Expert Panel Validation 115

Contact Us 115

Disclaimer 116


List Of Figure

List of Figures

Number of Products under Development for Spinal Muscular Atrophy (SMA), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Spinal Muscular Atrophy (SMA), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by AveXis Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Biogen Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Cytokinetics Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Genethon SA, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Genzyme Corp, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Kowa Company Ltd, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Neurotune AG, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Novartis AG, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Paratek Pharmaceuticals Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Recursion Pharmaceuticals Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Sarepta Therapeutics Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Scholar Rock Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Spotlight Innovation Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by Translate Bio Inc, H2 2017

Spinal Muscular Atrophy (SMA)-Pipeline by WAVE Life Sciences Ltd, H2 2017

Spinal Muscular Atrophy (SMA)-Dormant Projects, H2 2017

Spinal Muscular Atrophy (SMA)-Dormant Projects, H2 2017 (Contd..1), H2 2017

Spinal Muscular Atrophy (SMA)-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Spinal Muscular Atrophy (SMA) Therapeutic Products under Development, Key Players in Spinal Muscular Atrophy (SMA) Therapeutics, Spinal Muscular Atrophy (SMA) Pipeline Overview, Spinal Muscular Atrophy (SMA) Pipeline, Spinal Muscular Atrophy (SMA) Pipeline Assessment


Companies

Spinal Muscular Atrophy (SMA) Therapeutic Products under Development, Key Players in Spinal Muscular Atrophy (SMA) Therapeutics, Spinal Muscular Atrophy (SMA) Pipeline Overview, Spinal Muscular Atrophy (SMA) Pipeline, Spinal Muscular Atrophy (SMA) Pipeline Assessment